Current Report Filing (8-k)
August 23 2021 - 4:11PM
Edgar (US Regulatory)
0001583107
false
0001583107
2021-08-23
2021-08-23
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
Current Report Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event Reported):
August 23, 2021
THERAVANCE BIOPHARMA, INC.
(Exact Name of Registrant as Specified in
its Charter)
Cayman Islands
|
|
001-36033
|
|
98-1226628
|
(State or Other Jurisdiction of
|
|
(Commission File Number)
|
|
(I.R.S.
Employer Identification
|
Incorporation)
|
|
|
|
Number)
|
PO Box 309
Ugland House, South Church Street
George Town, Grand Cayman, Cayman Islands KY1-1104
(650) 808-6000
(Addresses, including zip code, and telephone
numbers, including area code, of principal executive offices)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
|
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of
the Act:
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
Ordinary Share $0.00001 Par Value
|
|
TBPH
|
|
NASDAQ Global
Market
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging
growth company ¨
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with
any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
The information in this Current Report (including Exhibits 99.1
and 99.2) is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange
Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Current Report (including Exhibits 99.1
and 99.2) shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933,
as amended, except as shall be expressly set forth by specific reference in such filing.
On August 23, 2021, Theravance Biopharma, Inc. issued a press release
and is holding a conference call to announce top-line results from its Phase 2b dose-finding induction study of izencitinib in patients
with ulcerative colitis. A copy of the press release is furnished as Exhibit 99.1 to this Current Report and a copy of materials that
will accompany the call is furnished as Exhibit 99.2 to this Current Report.
Item 9.01.
|
Financial Statements and Exhibits.
|
(d) Exhibits.
|
104
|
Cover Page Interactive Data File (cover page XBRL tags embedded within the Inline XBRL document)
|
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
|
THERAVANCE BIOPHARMA, INC.
|
|
|
Date: August 23, 2021
|
By: /s/ Andrew Hindman
|
|
Andrew Hindman
|
|
Senior Vice President and Chief Financial Officer
|
Theravance Biopharma (NASDAQ:TBPH)
Historical Stock Chart
From Aug 2024 to Sep 2024
Theravance Biopharma (NASDAQ:TBPH)
Historical Stock Chart
From Sep 2023 to Sep 2024